LENZ Therapeutics, Inc. Stock OTC Markets
Equities
GRPH
US52635N1037
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 20.46M | Capitalization | 401M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -70M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 19.6 x |
P/E ratio 2024 * |
-7.19
x | P/E ratio 2025 * |
-6.46
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.14% | - |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |